Inozyme Pharma is a biotechnology startup that develops new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone. Their focus in on diseases that largely impact infants, children, and young adults. Lead candidate is an enzyme replacement therapy designed to treat calcification disorders of the circulatory system, bone and kidney for which insufficient treatment options currently exist. The firm was founded in 2016 with technology licensed from Yale University that was developed in the lab of Demetrios Braddock.
500MM - 1B
700 Technology Sq
Cambridge, MA 02139
Top 10 Holders of Inozyme Pharma, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by